LM. The mechanism by which RhoA regulates vascular reactivity after hemorrhagic shock in rats. Am J Physiol Heart Circ Physiol 299: H292-H299, 2010. First published May 14, 2010; doi:10.1152 doi:10. /ajpheart.01031.2009 important member of the Rho family of GTPases, has been implicated in many cellular processes. Our pilot study found that RhoA participated in the regulation of vascular reactivity after shock, but the mechanism was incompletely understood. Whether RhoA regulates vascular reactivity through the Rho kinase-myosin light-chain phosphatase (MLCP) and Rac1-p21-activated kinase (PAK)-myosin lightchain kinase (MLCK) signaling pathway needs investigation. With isolated, superior mesenteric arteries from hemorrhagic-shock rats and hypoxia-treated vascular smooth muscle cells (VSMCs), the effects of U-46619 (RhoA agonist) and C3 transferase (RhoA antagonist) on vascular reactivity, and the relationship to the Rho kinase-MLCP and Rac1-PAK-MLCK signaling pathways were observed. The vascular reactivity of the superior mesenteric artery and the contractile response of VSMCs to norepinephrine after prolonged hemorrhagic shock and hypoxia (2 h) were significantly decreased. Activation of RhoA with U-46619 significantly increased shock or hypoxia-induced decreased vascular reactivity. These effects of U-46619 were abolished by Y-27632 (Rho kinase inhibitor) and PDGF (Rac1 stimulator). Y-27632 had a stronger antagonistic effect than PDGF. U-46619 increased the activity of Rho kinase and MLCK, enhanced the phosphorylation of 20-kDa myosin light chain, and decreased the activity of Rac1, PAK, and MLCP in VSMCs after hypoxia. Y-27632-antagonized U-46619 induced the decrease of MLCP activity and the increase of 20-kDa myosin light chain phosphorylation. PDGFantagonized U-46619 induced decrease of PAK activity and increase of MLCK activity. RhoA has an important role in the regulation of vascular reactivity after hemorrhagic shock. The Rho kinase-MLCP and Rac1-PAK-MLCK signal pathways participate in the regulatory process of RhoA. Rho kinase-MLCP may be the main signaling pathway by which RhoA regulates vascular reactivity. hemorrhagic shock; Rho kinase; Rac1; Rac1-p21-activated kinase RHOA IS ONE OF THE MAIN MEMBERS of the small G protein family. RhoA is widely distributed in various tissues. The Rho subfamily includes types A, B, and C (3). Besides participation in regulation of the cytoskeleton and cell adhesion, Rho proteins have been found to regulate cell polarity, endocytosis, vesicle trafficking, and gene transcription (8, 26) . Research showed that, after severe trauma, shock, and sepsis, vascular reactivity is significantly decreased; this severely interferes with the development, therapy, and the outcome of critical illness, including the shock state (5, 21, 22). Our pilot study found that the activity of RhoA was significantly decreased after prolonged shock and was positively correlated with reduced vascular reactivity, but the mechanism was incompletely understood.
longed shock and was positively correlated with reduced vascular reactivity, but the mechanism was incompletely understood.
Research has shown that the RhoA/Rho kinase pathway plays an important part in the regulation of vascular tone, and that this pathway participated in many cardiovascular diseases and pathophysiological conditions, such as hypertension, atherosclerosis, glucose metabolism, and insulin resistance (4) . Activation of Rho kinase by vasopressors, such as endothelin I or angiotension II, can significantly increase vascular tension (23, 28) . How RhoA regulates vascular reactivity during shock is not known.
Rho kinase is the main downstream molecule of RhoA. Research has shown that Rho kinase can participate in the regulation of vascular reactivity and vascular permeability after shock and burns via inhibition of myosin light-chain phosphatase (MLCP) to dephosphorylate 20-kDa myosin light chain (MLC 20 ) (12, 13) . Rac1 is the main member of the Rac subfamily and is widely distributed in epithelial cells, endothelial cells, vascular smooth muscle cells (VSMCs), and myocardial cells (25) . Basic research suggested that RhoA could inhibit Rac1 activity (6) . p21-activated kinase (PAK) is one of the important targets of Rac1, which could phosphorylate myosin light-chain kinase (MLCK) to decrease phosphorylation of MLC 20 (2) . Whether RhoA regulates vascular reactivity after shock through activation of the Rho kinase-MLCP pathway and inhibition of the Rac1-PAK-MLCK pathway needs to be determined.
The effects of the RhoA agonist U-46619 and the RhoA antagonist C3 exotransferase on vascular reactivity and their relationship to the Rho kinase-MLCP and Rac1-PAK-MLCK signaling pathway were observed using isolated superior mesenteric arteries (SMAs) from hemorrhagic shock rats and hypoxia-treated VSMCs used to mimic the hypoxic condition of the shock state.
MATERIALS AND METHODS

Animal Management
Experiments were carried out in accordance with the Research Council and Animal Care and Use Committee of the Research Institute of Surgery, Daping Hospital, Third Military Medical University (Chongqing, China). Experiments conformed to the guidelines of the ethical use of animals. The animal study protocol was reviewed and approved by the Animal Ethics Committee of Chongqing. Efforts were made to minimize animal suffering and to reduce the number of rats used. Male and female Sprague-Dawley (SD) rats (230 -260 g) were fasted 12 h, but allowed water ad libitum before experimentation.
Surgical Procedures and Preparation of a Hemorrhagic Shock Model
Rats were initially anesthetized with pentobarbital sodium (40 mg/kg iv). The right femoral arteries were catheterized with polyethylene tubing for monitoring the mean arterial pressure (MAP) and bleeding. To prevent clot formation, the tubing was filled with normal (0.9%) saline containing 30 U/ml of heparin. After completion of the surgical procedure, rats were allowed to stabilize for 10 min. They were rapidly hemorrhaged (within 10 min) from the right femoral arterial catheter until the MAP dropped to 40 mmHg. This MAP was maintained according to experimental design and used for subsequent experiments.
Preparation of VSMCs
VSMCs were obtained by enzymatic digestion of the mesenteric artery of SD rats and seeded into a transwell culture compartment, as described (19) . Before each experiment, cells were serum starved for 24 h. On the day of experiment, VSMCs in a transwell were put into a hypoxia culture compartment. This was bubbled into an atmosphere of 95% N 2 and 5% CO2 at 10 l/min for 10 min and then equilibrated for 5 min. This procedure was repeated thrice until the oxygen concentration in the culture compartment was Ͻ0.2% (1). The hypoxia time was based on the experimental design.
Experimental Protocols
Role of RhoA regulation of vascular reactivity after shock. IN VIVO. We used 2-h hemorrhagic shock rats to observe the effect of activation or inhibition of RhoA on the vascular reactivity of SMA to norepinephrine (NE). Fifty SD rats were randomly divided into 5 groups of 10: sham-operated, 2-h shock, 2-h shock ϩ U-46619, 2-h shock ϩ C3 transferase, and 2-h shock ϩ C3 transferase ϩ U-46619. Rats were intravenously given U-46619 (0.5 g/kg) or C3 transferase (50 g/kg) alone or in combination at 30 min before the end of shock (iv) in U-46619 or C3 transferase groups (C3 transferase is cell permeable; Cytoskeleton, Denver, CO). The pressor effect and the contractile response of SMA to NE (3 g/kg iv) was measured at 10, 20, 30, 40, and 50 min after the end of shock, namely 30, 40, 50, 60, and 70 min after U-46619 or C3 transferase administration with a polygraph physiological recorder (SP844, Power Laboratory; AD Instruments, Castle Hill, Australia) and an introvital video system (S6D Leica, Wetzlar, Germany). The contractile response of SMA was calculated using the following formula: 100% ϫ (D Ϫ D NE)/D. Where D is the diameter of the SMA before NE administration, and DNE is the diameter of the SMA after NE administration. The pressor effect of NE was expressed as the net increase of MAP after NE administration.
IN ISOLATED SMA. To exclude the neural and humoral interference in vivo and further demonstrate the role of RhoA regulation of vascular reactivity, 40 SMA rings taken from 2-h hemorrhagic shock rats and sham-operated rats, as described in our laboratory's previous work (16, 19) , were randomly divided into five groups of eight: sham-operated, 2-h shock, 2-h shock ϩ U-46619, 2-h shock ϩ C3 transferase, and 2-h shock ϩ C3 transferase ϩ U-46619. According to experimental design, artery rings were incubated with U-46619 (10 Ϫ8 mol/l) or C3 tranferase (60 g/l) alone or in combination for 30 min. The vascular reactivity of SMA to NE was then determined with an isolated organ perfusion system (Power Laboratories, AD Instruments, Castle Hill, Australia), as described (19, 32) . In brief, artery rings were mounted on wire and suspended between a force transducer and a post attached to a micrometer. They were then immersed into a 10-ml isolated organ chamber (Scientific Instruments, Barcelona, Spain) containing Krebs-Henseleit solution, which was continuously bubbled with 95% O 2/5% CO2, and the temperature was maintained at 25°C. Preload was given, 0.5 (g), and the KrebsHenseleit solution was replaced every 30 min. After equilibration for 2 h, the artery rings were incubated with U-46619 (10 Ϫ8 mol/l) or C3 tranferase (60 g/l) alone or in combination for 30 min, and the cumulative concentration-response curves of artery ring to NE were measured and constructed. The maximal contraction (Emax) and pD2 (Ϫlog 50% effective concentration) of agonists were obtained from the concentration-response curves and used to compare vascular reactivity. IN VSMCS. To search for a good model to mimic shock, the hypoxic condition, and to further confirm the role of RhoA regulation of vascular reactivity, hypoxia-treated VSMCs were used. VSMCs in a transwell received 2-h hypoxia. They were then divided into five groups: normal control, 2-h hypoxia, 2-h hypoxia ϩ U-46619, 2-h hypoxia ϩ C3 transferase, and 2-h hypoxia ϩ C3 transferase ϩ U-46619 (n ϭ 8 experiments per group). Hypoxia-treated VSMCs were incubated with U-46619 (10 Ϫ8 mol/l) or C3 tranferase (60 g/l) alone or in combination for 30 min. The contractile response of VSMC to NE (10 Ϫ5 mol/l) was assessed by cumulative fluorescent isothiocyanate (FITC)-labeled bovine serum albumin (BSA) from the upper compartment of the transwell, as described (16, 19) . Briely, 5 l of FITC-labeled BSA (4 mg/ml) and NE (10 Ϫ5 mol/l) were added into the upper compartment of transwell. One hundred microliters of medium were collected from the lower compartment. Fluorescence was measured at 1 h after adding NE, and 100 l of fresh medium were supplemented into the lower compartment after medium withdrawal. The contractile response of VSMC to NE was expressed as the infiltration rate of FITC-conjugated BSA (15) .
Mechanism of RhoA regulation of vascular reactivity after shock. To measure the effect of RhoA on the activity of Rho kinase and Rac1, VSMCs were divided into five groups: normal control, 2-h hypoxia, 2-h hypoxia ϩ U-46619, 2-h hypoxia ϩ C3 transferase, and 2-h hypoxia ϩ C3 transferase ϩ U-46619 (n ϭ 8 experiments/group). The concentration and incubation time of U-46619 and C3 transferase were similar to those described in Role of RhoA regulation of vascular reactivity after shock above. The activity of Rho kinase and Rac1 was determined based on previous descriptions (2, 6, 18) . Rac1 activities were assessed by a pull-down assay kit, in accordance with manufacturer's instructions (Rac1 activity kit, Pierce). Briefly, mesenteric arteries were washed with ice-cold Tris-buffered saline and lysate. Cell lysate (500 g) was incubated with GST-Pak1-PBD (Rac1) at 4°C. Beads were washed four times. Bound Rac1 were detected by Western blot analysis using a monoclonal antibody against Rac1. Activity was quantified by measuring the densitometry of the immunoblot bands(5). Rho kinase activity was measured with enzyme assay. The total protein was acquired with lysis buffer, 500 g of lysate protein were incubated with protein G Sepharose (15 l) at 4°C and centrifuged, and supernatant was incubated with anti-Rho kinase antiboby (6 g/tube) at 4°C and then incubated with protein G Sepharose (40 l). The immunoprecipitates were reacted with myosin and enzyme buffer (Tris·HCl, pH ϭ 7.5, 20 mmol/l, KCl 100 mmol/l, dithiothreitol 0.1 mmol/l, MgCl2 5 mmol/l, EDTA 1 mmol/l, microstin-LR 1 mol/l, [␥-32 P]ATP 100 nmol/l) for 5 min; the incorporation of 32 P was determined by liquid scintillation spectroscopy.
To measure the influence of Rho kinase and Rac1 on U-46619-induced increase of the contractile response of VSMCs to NE, VSMCs were divided into seven groups: normal control, 2-h hypoxia, 2-h hypoxia ϩ U-46619, 2-h hypoxia ϩ Y-27632 ϩ U-46619, 2-h hypoxia ϩ PDGF ϩ U-46619, 2-h hypoxia ϩ Y-27632, and 2-h hypoxia ϩ PDGF. The concentration of U-46619, Y-27632, and PDGF were 10 Ϫ8 mol/l, 10 Ϫ5 mol/l, and 20 g/l, respectively. The incubation time was 30 min. The contractile response of VSMCs to NE (10 Ϫ5 mol/l) was determined as described above.
RELATIONSHIP OF RHOA REGULATION OF VASCULAR REACTIVITY
TO MLCK, MLCP, AND MLC20 PHOSPHORYLATION. 1) Role of MLCK and MLCP in RhoA regulation of vascular reactivity. VSMCs from third to fifth passage received 2 h of hypoxia and were then divided into 2-h hypoxia, 2-h hypoxia ϩ U-46619, 2-h hypoxia ϩ ML-9 (MLCK inhibitor) ϩ U-46619, 2-h hypoxia ϩ calyculin A (MLCP inhibitor) ϩ U-46619, and ML-9 and calyculin A groups. The concentration of U-46619, ML-9, and calyculin A were 10 Ϫ8 , 10 Ϫ7 , and 10 Ϫ7 mol/l, respectively. The incubation time was 30 min. The contractile response of VSMC to NE (10 Ϫ5 mol/l) was determined as described above.
2) Relationship of RhoA regulation of vascular reactivity to MLC 20 phosphorylation. VSMCs from third to fifth passage received 2 h of hypoxia and were further divided into five groups of eight: normal control, 2-h hypoxia, U-46619, C3 transferase, and C3 transferase ϩ U-46619 groups. VSMCs were incubated with U-46619 (10 Ϫ8 mol/l) or C3 tranferase (60 g/l) alone or in combination for 30 min, and the proteins extracted. The level of MLC 20 phosphorylation was measured as described (9, 24 ). Treated VSMCs as described before were mixed with urea sample buffer consisting of 20 mM Tris base, 22 mM glycine, 10 mM dithiothreitol, 8 M urea, and 0.1% bromphenol blue and incubated for 1 h at room temperature. The homogenate was centrifuged at 13,000 g for 15 min at 4°C. Supernatant protein was collected and subjected to 10% glycerol-PAGE. Protein from glycerol-PAGE was transferred onto nitrocellulose membrane. Nitrocellulose membrane was incubated over night with anti-MLC 20 (Sigma, 1:200) and then incubated with HRP (Pierce, 1:8,000). The region containing MLC 20 was visualized using chemiluminescence. MLC20 phosphorylation level was expressed by the percentage of phosphorylated MLC 20 in total MLC20 (MLC20 ϩ phosphorylated MLC20).
REGULATORY EFFECTS OF RHOA ON THE ACTIVITY OF MLCP AND
Ϫ8 and 10 Ϫ5 mol/l, respectively. The incubation time with VSMCs was 30 min. The activity of MLCP in VSMCs was measured by enzyme assay (7, 9, 18, 24, 30) . MLCP activity in VSMC was assayed. Briefly, treated VSMCs were homogenized in Tris·HCl buffer. The homogenate was centrifuged, and the supernatant was collected. Ten microliters of supernatant protein were added to the 240 l of ice-cold buffer (25 mM Tris·HCl, pH 7.5, 0.1 mM EDTA, and 0.1% ␤-mercaptoethanol). The mixture was incubated at 25°C for 3 min, and then 20 l of 32 P-labeled myosin in 80 l of mixture were added and allowed to react for 15 min; 32 P-labeled myosin was prepared by MLCK and myosin as described. The reaction was stopped by adding 25% cold trichloroacetic acid and 5 mg/ml BSA. The stopped reactions were centrifuged. The 32 P of myosin that had not been dephosphorylated was determined by liquid scintillation spectroscopy.
REGULATORY EFFECTS OF RHOA ON THE ACTIVITY OF PAK AND MLCK AND ITS RELATIONSHIP TO RAC1. Experiments were divided into normal control, 2-h hypoxia, 2-h hypoxia ϩ U-46619, 2-h hypoxia ϩ PDGF ϩ U-46619, and 2-h hypoxia ϩ PDGF. The concentrations of U-46619 and PDGF were 10 Ϫ8 mol/l and 20 g/l, respectively. The incubation time with VSMCs was 30 min. The activity of MLCK in VSMCs was measured by enzyme assay, as described (1, 2, 19) . Treated VSMCs were homogenized with lysis buffer, the homogenate was centrifuged, and the supernatant was collected. Thirty microliters of supernatant protein were incubated with 60 l of enzyme buffer (Tris·HCl 30 mmol/l, pH 7.4, KCl 50 mmol/l, MgCl 2 1 mmol/l, 4-nitrophenylphosphate 60 mg/ml, PKA inhibitor 0.2 mg/ml, [␥-32 P]ATP 0.2 mmol/l, CaCl2 1 mmol/l, calmodulin 50 l g/ml, myosin 2 mg/ml) at 25°C for 3 min. The reaction was terminated by adding 10 l of 5% trichloroacetic acid. The incorporation of 32 P into myosin was determined by liquid scintillation spectroscopy. PAK activity was reflected by its phosphorylation, which was measured by Western blotting. PAK activity was expressed by the ratio of phosphorylated PAK (p-PAK) to total PAK.
Statistical Analysis
The concentrations of U-46619, Y-27632, PDGF, ML-9, and calyculin A were selected based on our pilot study. Data are means Ϯ SD of n observations. The difference between experimental groups was analyzed by one-way analysis of variance, followed by post hoc Tukey test. P Ͻ 0.05 was considered significant.
RESULTS
Role of RhoA Regulation of Vascular Reactivity After Shock
In vivo. The pressor and vasoconstriction effect of NE were significantly decreased after hemorrhagic shock. Activation of RhoA with U-46619 significantly increased the reduced pressor and vasoconstriction effect of NE, whereas inhibition of RhoA with C3 transferase further decreased the pressor and vasoconstriction effect of NE (Fig. 1, A and B) .
In isolated SMA. Compared with the sham-operated group, the vascular reactivity of the SMA was significantly decreased, the E max was decreased from 0.985 g/mg tissue in shamoperated group to 0.608 g/mg tissue. The RhoA agonist U-46619 at 10 Ϫ8 mol/l enhanced the contractile response of the SMA to NE (at 1 ϫ 10 Ϫ5 , 1 ϫ 10 Ϫ4 mol/l) (P Ͻ 0.05 or P Ͻ 0.01) 2 h after shock and shifted the cumulative dose-response curve of NE to the left. The E max of NE was 0.934 g/mg tissue and significantly increased compared with 2-h shock group. This effect of U-46619 on vascular reactivity was abolished by the RhoA antagonist C3 transferase (Fig. 1, C, D, and E) .
In VSMC. The contractile response of VSMCs to NE was significantly decreased after 2-h hypoxia. RhoA agonist, U-46619, increased the decreased contractile response of VSMC induced by hypoxia, while C3 transferase, the RhoA antagonist, further decreased the contractile response of VSMC and antagonized the effect of U-46619 (Fig. 1F) . 
Relationship of RhoA Regulation of Vascular Reactivity to Rho Kinase and Rac1
Effects of Y-27632 and PDGF on U-46619-induced increase of the contractile response of VSMCs to NE.
Compared with the normal control group, the contractile response of VSMCs to NE after 2 h of hypoxia was significantly decreased. The RhoA agonist U-46619 increased the contractile response of VSMCs to NE. The Rho kinase inhibitor Y-27632 decreased U-46619-induced increase of the contractile response of VSMCs to NE. The cumulative infiltration rate of FITC-BSA decreased from 54.89% in the U-46619 group to 33.18% in the Y-27632 ϩ U-46619 group; the ratio of decrease was 39.55%. Pretreatment with the Rac1 stimulator PDGF slightly decreased U-46619-induced increase of the contractile response of VSMCs to NE. The cumulative infiltration rate of FITC-BSA was 45.99% in the PDGF ϩ U-46619 group; the ratio of decrease was 16.21% ( Fig. 2A) .
Effect of U-46619 on the activity of Rho kinase and Rac1 in
VSMCs after hypoxia. The activity of Rho kinase and Rac1 was significantly decreased and increased, respectively, in VSMCs after 2 h of hypoxia compared with the normal control group. Activation of RhoA with U-46619 at 10 Ϫ8 mol/l increased the activity of Rho kinase and decreased the activity of Rac1. This effect of U-46619 was abolished by C3 transferase (RhoA specific inhibitor; Fig. 2, B and C) . RhoA in VSMC was ADP-ribosylated by cell-permeable C3 transferase (Fig. 2D) .
Relationship of RhoA Regulation of Vascular Reactivity to MLCK, MLCP, and MLC 20 Phosphorylation
Relationship to MLCK and MLCP. U-46619 (RhoA agonist) increased significantly hypoxia-induced decease of the contractile response of VSMCs to NE. ML-9 (MLCK inhibitor) reduced U-46619-induced increase of the contractile response of VSMC to NE; calyculin A (MLCP inhibitor) further increased U-46619-induced increase of the contractile response of VSMCs to NE (Fig. 3A) .
Relationship to MLC 20 phosphorylation. The level of MLC 20 phosphorylation in VSMCs was significantly reduced after 2 h of hypoxia. It fell from 51.22% in the normal control group to 32.72% in the 2-h hypoxia group. The RhoA agonist U-46619 significantly increased the hypoxiainduced decrease of MLC 20 phosphorylation level (it was 43.38%), whereas the RhoA inhibitor C3 transferase could further decrease MLC 20 phosphorylation level. This effect of U-46619 on MLC 20 phosphorylation level was abolished by C3 transferase (Fig. 3B) .
Regulatory Effect of RhoA on the Activity of MLCP and Its Relationship to Rho Kinase
As compared with normal control, 2 h of hypoxia significantly increased the activity of MLCP in VSMCs. The RhoA agonist U-46619 could decrease the increased activity of MLCP induced by hypoxia. This effect of U-46619 was abolished by the Rho kinase inhibitor Y-27632 (Fig. 4) .
Regulatory Effects of RhoA on the Activity of PAK and MLCK and Its Relationship to Rac1
PAK activity. Expression of p-PAK was slightly increased in VSMCs after 2 h of hypoxia; there was no significant difference compared with the control group(P Ͼ 0.05). U-46619 pretreatment significantly decreased the expression of p-PAK. To explore the regulatory effects of RhoA regulating PAK via Rac1, we used the Rac1 agonist PDGF. Our previous studies showed that PDGF at 20 ng/ml could activate Rac1, and that its role was antagonized by the Rac1-specific inhibitor NSC23766 (20) . These results showed that PDGF could significantly enforce p-PAK expression and abolish U-46619-induced decrease of p-PAK expression (Fig. 5A) .
MLCK activity. Hypoxia for 2 h could significantly decrease the activity of MLCK in VSMCs. U-46619 could slightly increase MLCK activity. Activation of Rac1 with PDGF could antagonize U-46619-induced increase of MLCK activity (Fig. 5B) .
DISCUSSION
The Rho-like subfamily includes RhoA, RhoB, and RhoC. There are few differences with respect to their upstream signaling molecules. The abnormality of the RhoA signal pathway is involved in many diseases, such as atherosclerosis, hypertension, and vascular spasm (14, 27) . Besides smooth musclerelated diseases, the RhoA signaling pathway has important roles in nonsmooth muscle-related diseases, such as chronic multiorgan inflammation fibrosis, and the infiltration and migration of tumors. The present study found that RhoA played an important part in the regulation of vascular reactivity under shock and hypoxia. Vascular reactivity and the contractile response of VSMCs to NE were significantly decreased after prolonged hemorrhagic shock and hypoxia. Activation of RhoA with U-46619 (0.5 g/kg in vivo, 10
Ϫ8 mol/l in vitro) could significantly increase shock or hypoxia-induced decrease of vascular reactivity.
Research had shown that RhoA had multitarget proteins. Rho kinase, as one of the important downstream moieties of RhoA, could increase the phosphorylation level of MLC 20 by inhibition of MLCP activity, increase the formation of stress fibers and focal adhesions, and increase the permeability of blood capillaries in some pathophysiological conditions, such as burns and sepsis (11) . Other studies found that more stress fibers could be induced by coexpression of the mammalian homolog of diaphanous, another effector of RhoA (17, 31) . Rac1 is the main member of the Rac subfamily and can be inhibited by RhoA. PAK is one of the important targets of Rac1, which could inhibit MLCK to decrease the phosphorylation of MLC 20 (2) . Whether RhoA regulates vascular reactivity through activation of the Rho kinase-MLCP pathway and inhibition of the Rac1-PAK-MLCK pathway under shock has not been determined. The present study showed that U-46619 (RhoA agonist) increased the activity of Rho kinase and MLCK, enhanced the phosphorylation of MLC 20 , and decreased the activity of Rac1, PAK, and MLCP in VSMCs after hypoxia. Y-27632 (Rho kinase-specific antagonist) could antagonize U-46619-induced decrease of MLCP activity and increase MLC 20 phosphorylation. A small dose of PDGF (Rac1 inhibitor) could antagonize U-46619-induced decrease of PAK activity and increase of MLCK activity. Y-27632 had a stronger antagonistic effect than PDGF. These findings suggested that RhoA played an important part in the regulation of vascular reactivity after shock, in which the Rho kinase-MLCP and the Rac1-PAK-MLCK pathway have important roles. In this process, Rho kinase was activated and Rac1 was inhibited; the Rho kinase-MLCP pathway is more important than the Rac1-PAK-MLCK pathway (Fig. 6) . Fig. 6 . Schematic overview of the mechanism in which RhoA regulates vascular reactivity after hemorrhagic shock in the present study. RhoA regulates vascular reactivity in hemorrhagic shock mainly via activation of the Rho kinase-MLCP pathway and inhibition of the Rac1-MLCK pathway to interfere with MLC20 phosphorylation level. Studies have shown that the mechanisms underpinning vascular hyporeactivity after shock may be related to functional disorders of the K ϩ and Ca 2ϩ channels in VSMCs, or the hyperpolarization of cell membrane. Our previous studies found that the calcium sensitivity of VSMCs was significantly decreased after shock, and that calcium desensitization played an important part in vascular hyporeactivity (32) . Protein kinase C took part in the regulation of vascular reactivity and calcium sensitivity though inhibition of MLCP activity and enforcement of MLC 20 phosphorylation after hemorrhagic shock. The present study found that RhoA had an important role in the regulation of vascular reactivity after shock. It exerted its effect mainly through activation of Rho kinase-MLCP and inhibition of the Rac1-PAK-MLCK pathway. This finding could provide a new regulatory target for the treatment of vascular hyporeactivity in shock, sepsis, and multiple-organ disorder syndrome.
We used the RhoA agonist U-46619 to demonstrate the effect of RhoA on vascular reactivity. U-46619 is not a specific agonist for RhoA. Cell-permeable C3 transferase (RhoA-specific inhibitor) was adopted to test the effect of U-46619 on RhoA. The exoenzyme C3 transferase (produced by expression in Escherichia coli as a His-tagged protein) is an ADP ribosyl transferase that selectively ribosylates RhoA on asparagine residue 41, rendering it inactive (29) . It has an extremely low affinity for other members of the Rho family, such as Cdc42 and Rac1, and, therefore, does not affect these GTPases. The present study indicated that cell-permeable C3 transferase can penetrate the cell membrane to ribosylate RhoA (Fig. 2D ) and antagonized U-46619 effect on vascular reactivity and Rho kinase and Rac1 activity ( Figs. 1 and 2 ). It was suggested that U-46619 had its effect mainly through activation of RhoA. To investigate if RhoA regulates vascular reactivity via the Rac1-PAK pathway, except for Rho kinase pathway, we used the Rac1 agonist PDGF as a tool agent. Although PDGF is not a specific Rac1 agonist, our laboratory's previous study found that small doses of PDGF (20 ng/ml) could selectively activate Rac1 to regulate the vascular reactivity following shock, and its effect could be abolished by the Rac1-specific inhibitor NSC23766 (20) . So we used a small dose of PDGF in the present study, and the result showed that this dose of PDGF regulated the vascular reactivity via Rac1-PAK pathway (Fig.  5) . Another study found that NSC23766 potently blocked PDGF-induced Rac1 activation and lamellipodia formation without affecting the activity of endogenous Cdc42 or RhoA (10) . It further showed that PDGF regulation of vascular reactivity seen in the present study is via Rac1.
Hypoxia-treated VSMCs in vitro were used to exclude some interfering factors in vivo and better elucidate the role of RhoA and related mechanisms. Hypoxia and ischemia are major factors contributing to the pathogenesis of hemorrhagic shock. Our previous studies showed that hypoxia in vitro could induce a biphasic change of the contractile response of VSMCs, which is similar to the biphasic change of vascular reactivity of the SMA during hemorrhagic shock in vivo (19) . This suggested the hypoxia-treated VSMCs in vitro could model the hypoxicischemic condition of shock. This hypoxia model only partially mimicked the shocked state, and a more appropriate model is needed to mimic the conditions of shock in future investigations.
Conclusion
RhoA played an important part in the regulation of vascular reactivity after shock, in which the Rho kinase-MLCP and Rac1-PAK-MLCK pathways had important roles. In this process, Rho kinase was activated, and Rac1 was inhibited; the Rho kinase-MLCP pathway was more important than the Rac1-PAK-MLCK pathway. The present study proved that RhoA had an important role in the regulation of vascular reactivity after shock, and the primary mechanism was elucidated. Which factors can regulate RhoA, and whether RhoA can be a therapeutic target for vascular hyporeactivity in critical illnesses needs further investigation.
